Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

8.4%

40 terminated/withdrawn out of 475 trials

Success Rate

86.9%

+0.4% vs industry average

Late-Stage Pipeline

24 trials in Phase 3/4

Results Transparency

32%

86 of 266 completed trials have results

Key Signals

96 recruiting86 with results35 terminated5 withdrawn

Enrollment Performance

Analytics

N/A

90(30.4%)

Phase 2

90(30.4%)

Phase 1

89(30.1%)

Phase 3

21(7.1%)

Early Phase 1

3(1.0%)

Phase 4

3(1.0%)

296Total

N/A(90)

Phase 2(90)

Phase 1(89)

Phase 3(21)

+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (475)

Showing 20 of 475 trials

NCT01857934Phase 2Completed

Therapy for Children With Advanced Stage Neuroblastoma

Role: lead

NCT05164016Completed

Evaluating Immune Response to COVID-19 Vaccines in Patients With Cancer, Transplant or Cellular Therapy Recipients

Role: lead

NCT07392216Recruiting

Functional Ovarian Reserve in Sickle Cell Disease

Role: lead

NCT04897321Phase 1Recruiting

B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)

Role: lead

NCT07008027Not Yet Recruiting

Real World Asparaginase Therapy Toxicity

Role: lead

NCT07531498Not Yet Recruiting

Muscle Aging Phenotypes in Childhood Cancer Survivors

Role: lead

NCT07444216Recruiting

A Longitudinal Photo-Narrative Exploration of Hope During Phase 1/2 Clinical Trials For Pediatric Cancer

Role: lead

NCT03016156Not ApplicableTerminated

Determination of the Sensitivity and Specificity of a Smartphone Application to Detect Retinoblastoma

Role: lead

NCT03849651Phase 2Active Not Recruiting

TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies

Role: lead

NCT04901702Phase 1Recruiting

Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma

Role: lead

NCT07228741Phase 2Recruiting

Resistance Exercise and Incretin Mimetic for Cardiometabolic Health in Survivors of ALL With Obesity

Role: lead

NCT05955261Phase 2Suspended

A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia

Role: lead

NCT07257419Phase 1Recruiting

CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma

Role: lead

NCT03226158Active Not Recruiting

Next Generation Pathogen Sequencing for Prediction of Adverse Events

Role: lead

NCT05932914Not Yet Recruiting

Liver Biopsy Following Gene Therapy For Hemophilia

Role: lead

NCT07314736Recruiting

Stakeholders of Rare Diseases Informing Values In Neuroethics

Role: lead

NCT00979238Phase 1Completed

Dose-Escalation Study Of A Self Complementary Adeno-Associated Viral Vector For Gene Transfer in Hemophilia B